Menopause Annual Evaluation Checklist: What to Review Every Year

What Is a Menopause Annual Evaluation?

A menopause annual evaluation is a structured clinical visit that systematically reviews symptom burden, therapy safety, and preventive screening for women in perimenopause or post-menopause. It exists because menopause is not a single event, it is a multi-decade biological state carrying evolving risks to bone, heart, brain, and urogenital tissue.

The NAMS 2022 Hormone Therapy Position Statement states directly: "The risks of hormone therapy differ by type, dose, route of administration, timing of initiation, and duration of use." That complexity means a one-time prescription without annual monitoring is inadequate care. [1]

Why Annual, Not as-Needed

Symptom-driven visits miss asymptomatic disease. A woman whose hot flashes have resolved may feel she no longer needs follow-up, yet her bone mineral density may be declining silently. The WHI Memory Study and subsequent analyses showed that timing of estrogen exposure relative to menopause onset changes both benefit and risk profiles, a fact that makes date-of-menopause tracking a clinical necessity at every visit. [2]

Who Needs This Checklist

Any woman who has gone 12 consecutive months without a menstrual period qualifies as post-menopausal regardless of age. Women in perimenopause, defined by irregular cycles plus vasomotor or genitourinary symptoms, benefit from the same annual review framework, with the addition of cycle-pattern documentation.

Section 1: Symptom Review

Vasomotor Symptoms (Hot Flashes and Night Sweats)

Hot flashes affect roughly 75% of menopausal women, and severe symptoms persist for a median of 7.4 years according to the SWAN (Study of Women's Health Across the Nation) cohort. [3] At each annual visit, use a validated tool such as the Menopause Rating Scale (MRS) or the Greene Climacteric Scale to score symptom frequency and severity. A numeric score allows objective comparison year over year.

Ask specifically about:

• Frequency per 24 hours
• Severity (mild, moderate, severe, very severe)
• Sleep disruption nights per week
• Daytime work or social impairment

If a patient rates symptoms as moderate-to-severe and is not on therapy, revisit the risks and benefits of systemic estrogen. NAMS 2022 and the Endocrine Society 2015 Clinical Practice Guideline both support initiating hormone therapy in healthy women under 60 or within 10 years of menopause when vasomotor symptoms impair quality of life. [1][4]

Genitourinary Syndrome of Menopause (GSM)

GSM, vaginal dryness, dyspareunia, urinary urgency, recurrent UTIs, affects up to 50% of post-menopausal women yet is underreported in routine visits. [5] Ask directly. Vaginal pH above 5.0 on exam supports the diagnosis. Local low-dose vaginal estrogen (estradiol 10 mcg cream or ring, or prasterone 6.5 mg vaginal insert) is first-line and carries negligible systemic absorption at approved doses. [5]

Mood and Cognitive Concerns

Depressive symptoms peak during the menopause transition. The SWAN data showed a 1.7-fold increased risk of a depressive episode during perimenopause compared to premenopause. [3] Ask about sleep quality, concentration, and mood changes separately from hot-flash-driven sleep disruption. Distinguish new-onset depression from cognitive aging using validated tools such as the PHQ-9 for depression and the MoCA for cognitive screening when indicated.

Section 2: Hormone Therapy Review

Current Regimen Audit

For any patient on hormone therapy, the annual visit should document:

• Estrogen type (estradiol, conjugated equine estrogen), dose, and route (oral, transdermal patch, gel, spray, vaginal ring)
• Progestogen type (micronized progesterone 100-200 mg, medroxyprogesterone acetate, levonorgestrel IUD) and dose for women with a uterus
• Duration of current therapy
• Reason for any dose changes since last visit

Transdermal estradiol does not increase venous thromboembolism risk the way oral estrogens do, based on the French E3N cohort study (N=80,377). [6] That distinction matters when reassessing route of delivery annually.

The "Timing Hypothesis" in Practice

The WHI randomized trial (conjugated equine estrogen 0.625 mg plus medroxyprogesterone acetate 2.5 mg, N=16,608) enrolled women whose average age was 63, more than a decade past menopause. [2] Subsequent re-analysis by age group showed that women aged 50-59 at randomization had a non-significant trend toward reduced coronary heart disease events, while older starters did not. This age-stratified finding underpins the current "timing hypothesis": initiate HRT close to menopause for cardioprotection, not years later.

Document the patient's age at menopause and years since menopause at every visit. A woman who started estrogen at year 11 post-menopause should be counseled differently than one who started at year 1.

When to Consider Dose Reduction or Discontinuation

There is no mandated time limit on hormone therapy for healthy, symptomatic women according to NAMS 2022. [1] Annual reassessment should weigh:

• Ongoing symptom burden (justifies continuation)
• New cardiovascular, thromboembolic, or breast cancer diagnoses (may require cessation)
• Patient preference after full discussion of updated risk data

If a patient chooses to stop, a gradual taper over 3-6 months reduces recurrent vasomotor symptoms compared to abrupt cessation in most clinical experience, though randomized tapering trial data remain limited.

Section 3: Laboratory and Metabolic Panel

Core Annual Labs

Order these at every annual menopause evaluation:

• Fasting lipid panel. Estrogen deficiency accelerates LDL-C rise. The Framingham Heart Study data showed post-menopausal women have substantially higher age-adjusted cardiovascular event rates than premenopausal peers. [7]
• Fasting glucose and HbA1c. Type 2 diabetes incidence increases after menopause. NAMS recommends metabolic screening annually in post-menopausal women. [1]
• TSH. Hypothyroidism shares symptoms with menopause (fatigue, weight gain, mood changes). Prevalence of overt hypothyroidism in women over 50 is approximately 2-5%. [8]
• Comprehensive metabolic panel. Monitor liver and kidney function, especially in patients on oral HRT or statin therapy.

Hormone-Specific Labs

FSH and estradiol are not required at every visit once menopause is confirmed by 12 months of amenorrhea, but they are useful in:

• Women under 45 where premature ovarian insufficiency (POI) is a concern (FSH >25.8 mIU/mL on two measurements 4 weeks apart) [4]
• Perimenopausal women on combined hormonal contraception where cycle pattern is masked
• Assessment of therapy adequacy when symptoms persist despite treatment

Serum estradiol on transdermal therapy is variable; measure 3-4 days after last patch application or the morning before the next gel dose for a representative trough value.

Vitamin D and Calcium Status

Vitamin D deficiency affects bone mineralization and correlates with fall risk. The Endocrine Society Clinical Practice Guideline recommends maintaining serum 25-hydroxyvitamin D above 30 ng/mL in adults at risk for deficiency. [9] Test 25(OH)D annually in post-menopausal women, particularly those with limited sun exposure, darker skin tone, BMI above 30, or malabsorption conditions.

Section 4: Bone Health

DXA Scanning Schedule

Dual-energy X-ray absorptiometry (DXA) measures bone mineral density at the lumbar spine and hip. The National Osteoporosis Foundation (now part of the American Bone Health organization) and the Endocrine Society recommend initiating DXA at age 65 for average-risk women. [4] Earlier scanning is indicated for:

• Early menopause or POI
• Prolonged corticosteroid use (>3 months)
• Fragility fracture history
• BMI <18.5
• Current smoking

For women already on HRT for bone protection, repeat DXA every 2 years. For women not on therapy with baseline osteopenia (T-score between -1.0 and -2.5), repeat every 1-2 years based on rate of loss.

FRAX Scoring

The FRAX tool (developed by the WHO Collaborating Centre for Metabolic Bone Diseases) calculates 10-year fracture probability. [10] Input it at every annual visit when DXA is available. A FRAX 10-year major osteoporotic fracture probability >20%, or hip fracture probability >3%, crosses the NAMS/NOF threshold for initiating pharmacotherapy even without a DXA-confirmed osteoporosis diagnosis.

Pharmacotherapy Options

If osteoporosis (T-score <-2.5) or high FRAX probability is present, discuss:

• Bisphosphonates (alendronate 70 mg weekly, risedronate 35 mg weekly): first-line for most women
• Raloxifene 60 mg daily: reduces vertebral fracture risk and has favorable breast cancer data (MORE trial, N=7,705, 76% relative risk reduction for invasive breast cancer vs. Placebo) [11]
• Estrogen/HRT: acceptable for bone protection in women who also have vasomotor symptoms; does not require additional bisphosphonate unless osteoporosis is severe

Section 5: Cardiovascular Risk

Annual Cardiovascular Assessment

Cardiovascular disease is the leading cause of death in post-menopausal women in the United States. [7] The annual evaluation should include:

• Blood pressure measurement (target <130/80 mmHg per AHA/ACC 2017 guidelines) [12]
• Fasting lipid panel (reviewed in Section 3)
• Body weight and waist circumference
• Smoking status update
• Physical activity level

Calculate a 10-year ASCVD risk score (Pooled Cohort Equations) at least every 4 years, or annually if borderline-to-intermediate risk (7.5-20%).

Statin Consideration

Post-menopausal LDL-C rise may cross ACC/AHA thresholds for statin initiation. The ACC/AHA 2019 guideline recommends initiating statin therapy when 10-year ASCVD risk is >7.5% and LDL-C is >70 mg/dL in patients with additional risk-enhancing factors. [13] Menopause itself is listed as a risk-enhancing factor in that guideline, a point that should be communicated explicitly to patients.

Blood Pressure Management in HRT Users

Transdermal estradiol is generally neutral or mildly favorable for blood pressure. Oral conjugated equine estrogen can raise blood pressure in some women via renin-angiotensin system activation. If blood pressure rises after starting oral HRT, switching to transdermal is a reasonable first step before adding antihypertensive medication.

Section 6: Cancer Screening

Breast Cancer Screening

The ACR (American College of Radiology) recommends annual mammography beginning at age 40 for average-risk women. [14] The USPSTF 2024 updated draft recommends starting at age 40, aligning more closely with ACR. Women on combined estrogen-progestogen therapy have a modestly increased breast cancer risk (hazard ratio approximately 1.26 in the WHI, with absolute risk of about 8 additional cases per 10,000 women-years). [2] That risk does not preclude HRT in appropriate candidates, but it does make consistent annual mammography non-negotiable.

Women with a first-degree relative with breast cancer or known BRCA1/2 pathogenic variant should be referred for high-risk screening protocols including MRI.

Cervical and Endometrial Screening

Cervical cancer screening follows standard intervals: Pap smear every 3 years (ages 21-65) or co-testing with HPV every 5 years (ages 30-65), per ASCCP 2019 guidelines. Menopause status does not change these intervals.

Endometrial cancer risk increases with unopposed estrogen. Any post-menopausal uterine bleeding, even spotting, requires endometrial biopsy or transvaginal ultrasound with endometrial stripe measurement. An endometrial thickness below 4 mm on transvaginal ultrasound has a negative predictive value of 99% for endometrial carcinoma. [15] Women on micronized progesterone or a progestogen-releasing IUD have endometrial protection confirmed by both histologic and imaging data.

Colorectal Screening

Post-menopausal women have the same colorectal cancer screening obligations as age-matched men. The American Cancer Society recommends initiating screening at age 45 for average-risk adults, with colonoscopy every 10 years being the preferred modality. [16] HRT use is associated with a modest reduction in colorectal cancer risk (relative risk approximately 0.80 in observational data), but this benefit does not replace screening.

Section 7: Lifestyle and Non-Pharmacologic Management

Physical Activity Targets

The 2018 Physical Activity Guidelines for Americans recommend 150-300 minutes of moderate-intensity aerobic activity weekly plus 2 days of muscle-strengthening exercise. [17] In post-menopausal women, resistance training specifically reduces rate of bone mineral density loss and improves insulin sensitivity. At each annual visit, ask about current activity and document barriers.

Nutrition Assessment

Calcium and vitamin D intake should be reviewed. The National Institutes of Health Office of Dietary Supplements recommends 1,200 mg elemental calcium daily for women over 50, preferably from food, and 600-800 IU vitamin D3 daily. [18] Supplement only the gap between dietary intake and target; calcium supplementation above 1,000 mg/day from supplements (not food) has been associated with modest increases in cardiovascular event risk in some cohort studies.

Sleep and Mental Health

Sleep-disordered breathing prevalence increases after menopause. If a patient reports waking unrefreshed, loud snoring, or witnessed apneas, refer for polysomnography before attributing all sleep disruption to vasomotor symptoms. Cognitive behavioral therapy for insomnia (CBT-I) is first-line for chronic insomnia in this population before any sedative-hypnotic prescription.

Section 8: The Annual Visit Summary Template

The following framework consolidates each domain into a one-page clinical checklist for the annual menopause visit. Clinicians can adapt this to their EHR template.

A. Symptom Scores

• Menopause Rating Scale (MRS) total and subscale scores
• GSM symptom score (0-10 numeric rating)
• PHQ-9 if mood concerns flagged

B. Therapy Review

• Current HRT: drug, dose, route, duration
• Last dose change date and reason
• Adherence assessment
• Side effects since last visit

C. Labs Ordered or Reviewed

• Fasting lipid panel (LDL-C, HDL-C, triglycerides)
• Fasting glucose and HbA1c
• TSH
• 25-hydroxyvitamin D
• Comprehensive metabolic panel
• FSH/estradiol (if indicated)

D. Imaging and Procedures

• DXA date, T-score at lumbar spine and total hip
• FRAX 10-year probability
• Mammogram date and result
• Colonoscopy date (or alternative colorectal screen)
• Pap/HPV co-test date

E. Cardiovascular

• Blood pressure (both readings if elevated)
• 10-year ASCVD score
• Statin status
• Waist circumference

F. Lifestyle

• Weekly minutes of aerobic activity
• Resistance training days per week
• Dietary calcium estimate (mg/day)
• Smoking status
• Alcohol units per week

G. Plan

• Therapy continuation, dose adjustment, or discontinuation rationale
• Referrals (GYN-oncology, endocrinology, sleep medicine, cardiology)
• Next DXA date
• Recall interval